PURPOSE: Recurrent prostate cancer is usually treated by combining radiotherapy and androgen deprivation therapy. To stage the cancer, choline positron emission tomography (PET)/CT can be performed. It is generally thought that androgen deprivation therapy does not influence choline PET/CT. In this article we focus on the molecular backgrounds of choline and androgens, and the results of preclinical and clinical studies performed using PET/CT. METHODS: Using PubMed, we looked for the relevant articles about androgen deprivation therapy and choline PET/CT. RESULTS: During ADT, a tendency of decreased uptake of choline in prostate cancer was observed, in particular in hormone-naïve patients. CONCLUSION: We conclude that in order to prevent false-negative choline PET/CT scans androgen deprivation should be withheld prior to scanning, especially in hormone-naïve patients.
PURPOSE: Recurrent prostate cancer is usually treated by combining radiotherapy and androgen deprivation therapy. To stage the cancer, choline positron emission tomography (PET)/CT can be performed. It is generally thought that androgen deprivation therapy does not influence choline PET/CT. In this article we focus on the molecular backgrounds of choline and androgens, and the results of preclinical and clinical studies performed using PET/CT. METHODS: Using PubMed, we looked for the relevant articles about androgen deprivation therapy and choline PET/CT. RESULTS: During ADT, a tendency of decreased uptake of choline in prostate cancer was observed, in particular in hormone-naïve patients. CONCLUSION: We conclude that in order to prevent false-negative choline PET/CT scans androgen deprivation should be withheld prior to scanning, especially in hormone-naïve patients.
Authors: T R DeGrado; R E Coleman; S Wang; S W Baldwin; M D Orr; C N Robertson; T J Polascik; D T Price Journal: Cancer Res Date: 2001-01-01 Impact factor: 12.701
Authors: Martin Heinisch; Albert Dirisamer; Wolfgang Loidl; Franz Stoiber; Bernhard Gruy; Silke Haim; Werner Langsteger Journal: Mol Imaging Biol Date: 2006 Jan-Feb Impact factor: 3.488
Authors: Ludwig Rinnab; Felix M Mottaghy; Norbert M Blumstein; Sven N Reske; Richard E Hautmann; Kathrin Hohl; Peter Möller; Thomas Wiegel; Rainer Kuefer; Juergen E Gschwend Journal: BJU Int Date: 2007-10 Impact factor: 5.588
Authors: Mohsen Beheshti; Reza Vali; Peter Waldenberger; Friedrich Fitz; Michael Nader; Josef Hammer; Wolfgang Loidl; Christian Pirich; Ignac Fogelman; Werner Langsteger Journal: Mol Imaging Biol Date: 2009 Nov-Dec Impact factor: 3.488
Authors: M Picchio; P Mapelli; V Panebianco; P Castellucci; E Incerti; A Briganti; G Gandaglia; M Kirienko; F Barchetti; C Nanni; F Montorsi; L Gianolli; S Fanti Journal: Eur J Nucl Med Mol Imaging Date: 2015-01-17 Impact factor: 9.236